For biotechs
Find out whether your lead candidate has a credible route into the eye, before you commit serious capital.
A good chance of success
71.6%vs 52.0%
Ophthalmic drugs move from Phase I to Phase II more often than in any other disease area. We tell you whether yours belongs in the eye before you commit serious capital.
More investable
2.9xvs 1.7x
A drug that treats more than one indication returns 2.9x from preclinical to approval, against 1.7x for one alone. The evidence plan and the patent position are what let you claim the second one and show the risk coming down.
Attractive to big pharma
US$1.3Bupfront
Paid by Merck for EyeBio in 2024, with its lead candidate still in early clinical trials. Large pharma now sources 55% of new drugs from outside its own laboratories, and buys once early clinical risk is retired.